MRD Assessment in Multiple Myeloma: Progress and Challenges
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s11899-021-00633-5.pdf
Reference63 articles.
1. •• Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–99 A recent meta-analysis on around 8000 patients from different MRD studies, confirming the important prognostic impact of the achievement of MRD negativity, regardless of the adopted method (next-generation sequencing [NGS] or multiparameter flow cytometry [MFC]), time point, and setting (diagnosis or relapse).
2. Oliva S, D’Agostino M, Boccadoro M, Larocca A. Clinical applications and future directions of minimal residual disease testing in multiple myeloma. Front Oncol. 2020;10. https://doi.org/10.3389/fonc.2020.00001.
3. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.
4. •• Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35:18–30 An international expert consensus on how to report MRD analysis, to foster the standardization and comparison among different studies.
5. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90:61–72.
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories;Annals of Laboratory Medicine;2024-08-20
2. Calls to action on lung cancer management and research;The Oncologist;2024-07-13
3. Changes in practice within a haematological malignancy diagnostic service: A 5‐year retrospective study;British Journal of Haematology;2024-05-12
4. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions;Current Oncology Reports;2024-04-27
5. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-04-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3